drugset / Trial / NCT01615627

Hypotonic Treprostinil Subcutaneous Infusion for Control of Treprostinil Related Site Pain

NCT01615627

Phase 4 Withdrawn Jewish General Hospital
RandomizedCrossoverQuadruple-blindTreatment

Summary

The investigators will test whether hypotonic (diluted) remodulin solution causes less pain than the eutonic (undiluted) solution supplied by the manufacturer.

Timeline

Start
2012-07-01
Primary completion
2019-02-28
Completion
2019-02-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Treprostinil Other / unclassified